In a recent article published in Forbes, COTA CEO Mike Doyle discussed the devastating impact COVID-19 has had on cancer care given delayed screenings and missed treatment windows. As a result of these care delays, more patients are expected to present with advanced cancer when they eventually seek care from an oncologist.
To address this issue, Doyle outlined the critical role real-world data can play in helping us better understand the complex interplay of COVID-19 and various forms and stages of cancer. He further explained how a retrospective study of pandemic-related treatment variation can help us gain new insights about adherence to or deviation from standard pathways and their impact on patient outcomes.
You can read more about the impact real-world data can have in improving cancer care despite pandemic-related setbacks here: Getting Cancer Care Back on Track with RWD.
